[Anti-arrhythmia and antifibrillatory properties of dibenzazepine derivatives].
Antiarrhythmic and antifibrillation properties of bonnecor, a derivative of dibenzepin, were studied in comparison with ethmozine, quinidine and novocainamide, using various experimental arrhythmia models. Bonnecor activity was somewhat smaller than that of ethmozine, and much greater than that of quinidine and novocainamide in the mixed atrioventricular arrhythmia model simulated in aconitin-treated rats and the ventricular arrhythmia model simulated by two-degree coronary occlusion in dogs. Intravenous 1 mg/kg and oral 6 mg/kg bonnecor doses prevented ventricular fibrillation caused by acute coronary occlusion in rats, while ethmozine showed no such effect.
D000157:Aconitine / Q000633:toxicity; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy; D003984:Dibenzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D011817:Rabbits; D051381:Rats; D013328:Strophanthins / Q000633:toxicity; D013329:Structure-Activity Relationship
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; D013328:Strophanthins; D000157:Aconitine
Antiaritmicheskie i antifibrilliatornye svoĭstva proizvodnykh dibenzazepina.